| Literature DB >> 28428751 |
Chunlan Hong1, Anja Schüffler2,3, Ulrich Kauhl4, Jingming Cao1, Ching-Fen Wu1, Till Opatz4, Eckhard Thines2,3, Thomas Efferth1.
Abstract
Posttraumatic stress disorder (PTSD) is a mental disorder developing after exposure to traumatic events. Although psychotherapy reveals some therapeutic effectiveness, clinically sustainable cure is still uncertain. Some Chinese herbal formulae are reported to work well clinically against mental diseases in Asian countries, but the safety and their mode of action are still unclear. In this study, we investigated the mechanisms of Chinese remedy free and easy wanderer (FAEW) on PTSD. We used a reverse pharmacology approach combining clinical data to search for mechanisms of PTSD with subsequent in vitro verification and bioinformatics techniques as follows: (1) by analyzing microarray-based transcriptome-wide mRNA expression profiling of PTSD patients; (2) by investigating the effect of FAEW and the antidepressant control drug fluoxetine on the transcription factor NF-κB using reporter cell assays and western blotting; (3) by performing molecular docking and literature data mining based on phytochemical constituents of FAEW. The results suggest an involvement of inflammatory processes mediated through NF-κB in the progression of PTSD. FAEW was non-cytotoxic in vitro and inhibited NF-κB activity and p65 protein expression. FAEW's anti-inflammatory compounds, i.e., paeoniflorin, isoliquiritin, isoliquiritin apioside and ononin were evaluated for binding to IκK and p65-RelA in a molecular docking approach. Paeoniflorin, albiflorin, baicalin, isoliquiritin and liquiritin have been reported to relieve depression in vivo or in clinical trials, which might be the active ingredients for FAEW against PTSD.Entities:
Keywords: NF-κB; free and easy wanderer; inflammation; pharmacognosy; posttraumatic stress disorder
Year: 2017 PMID: 28428751 PMCID: PMC5382210 DOI: 10.3389/fphar.2017.00181
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1The structures of 10 compounds isolated from FAEW.
Figure 2The top 10 canonical pathways significantly affected by PTSD. (A) Blood-based gene-expression according to [15]; (B) Peripheral blood mononuclear cell gene expression profiles according to [16]; (C) Monocyte gene expression profiles according to [13]; (D) Post mortem brain biopsy gene expression profiles according to [14].
Figure 3Top 10 diseases and functions significantly affected by PTSD. (A) Blood-based gene-expression according to [15]; (B) Peripheral blood mononuclear cell gene expression profiles according to [16]; (C) Monocyte gene expression profiles according to [13]; (D) Post mortem brain biopsy gene expression profiles according to [14].
Figure 4Deregulated genes among PTSD patients. Red colored genes were up-regulated, green colored ones were down-regulated. The arrows indicted effects of deregulated genes on other genes. Continuous lines show direct interactions, dotted lines indirect interactions. (A) Blood-based gene-expression according to [15]; (B) Peripheral blood mononuclear cell gene expression profiles according to [16]; (C) Monocyte gene expression profiles according to [13]; (D) Post mortem brain biopsy gene expression profiles according to [14].
The most pronounced gene promoter binding motifs depending on the integrative analysis of Galaxy/Cistrome.
| 1 | IKZF2|Ikzf2 | 33 | 8.733 | −5.25 | 163.693 |
| 2 | CAT8 | 21 | 8.035 | −5.16 | 159.248 |
| 3 | CCDC16 | 70 | 6.592 | −5.09 | 155.157 |
| 4 | HOXA1 | 285 | 5.666 | −4.94 | 147.672 |
| 5 | HOXD10|Hoxd10 | 175 | 7.493 | −4.90 | 145.427 |
| 6 | Meox1 | 235 | 6.41 | −4.87 | 144.123 |
| 7 | E2F1::TFDP1 | 569 | 4.626 | −4.85 | 143.061 |
| 8 | Sfpi1 | 179 | 6.952 | −4.72 | 136.281 |
| 9 | Mox1|MEOX1|CD200|NOX1 | 245 | 6.333 | −4.66 | 133.664 |
| 10 | CBFA2T2 | 233 | 4.945 | −4.65 | 133.291 |
| 11 | DAL81 | 72 | 4.577 | −4.61 | 130.914 |
| 12 | Etv1 | 137 | 6.035 | −4.60 | 130.538 |
| 13 | Hoxa1 | 267 | 5.713 | −4.57 | 129.11 |
| 14 | FOXP4 | 211 | 5.907 | −4.55 | 128.263 |
| 15 | Nkx1-1 | 104 | 6.226 | −4.54 | 127.587 |
| 16 | lhx6.1|LHX6 | 499 | 4.368 | −4.43 | 122.535 |
| 17 | MET4 | 340 | 5.212 | −4.41 | 121.631 |
| − | |||||
| 19 | ACE2 | 537 | 6.774 | −4.25 | 114.451 |
| 20 | Muscle TATA box | 1242 | 1.144 | −4.23 | 113.4 |
Bold values are possible transcriptional motif related to NF-κB shown in the networks analysis.
Figure 5Detailed information of the NF-κB binding motif in gene promoter sequences.
Figure 6Cytotoxicity of FAEW (A) and fluoxetine (B) as determined by the resazurin assay. Shown are mean values ± SD of three independent experiments.
Figure 7Inhibition of NF-κB activity by FAEW and fluoxetine in HEK293 reporter cells. (A) Concentration kinetics and (B) time kinetics shown are mean values ± SD of three independent experiments. *p < 0.05, **p < 0.01. The inhibition effects of FAEW and fluoxetine toward NF-κB activity were calculated by comparison with untreated TNF-α induction group.
Figure 8Inhibition of p65 expression by FAEW and fluoxetine in T98G brain cells. (A) Concentration kinetics and (B) time kinetics. Histone was used as loading control. (C,D) show the quantification of western blots shown in (A,B), respectively. The inhibition effects of FAEW and fluoxetine toward p65 protein expression were calculated by comparison with untreated TNF-α induction group after using the control group without TNF-α for the quantification of western blots. Shown are mean values ± SD of three independent experiments. *p < 0.05, **p < 0.01.
Binding energies of molecular docking of chemical compounds of FAEW to proteins of the NF-κB pathway.
| Baicalin | −3.79 ± 0.50 | 1690 ± 155.56 | −5.97 ± 0.04 | 42.47 ± 2.43 | −9.68 ± 0.09 | 79.88 ± 11.99 |
| β-hydroxy-DHP | −5.04 ± 0.05 | 203.52 ± 18.09 | −5.87 ± 0.18 | 52.24 ± 14.46 | −8.54 ± 0.04 | 553.70 ± 33.52 |
| Isoliquiritin | −3.59 ± 0.17 | 2390.00 ± 692.97 | −7.04 ± 0.08 | 6.92 ± 0.98 | −9.97 ± 0.22 | 61.00 ± 4.24 |
| Isoliquiritin apioside | −1.20 ± 0.12 | 132.78 ± 28.65 | −6.90 ± 0.15 | 9.00 ± 2.28 | −10.10 ± 0.74 | 56.59 ± 8.56 |
| Liquiritin | −4.12 ± 0.28 | 1155.00 ± 247.49 | −6.10 ± 0.19 | 34.91 ± 11.08 | −9.20 ± 0.04 | 180.31 ± 14.99 |
| Ononin | −3.82 ± 0.02 | 1600.00 ± 70.71 | −7.33 ± 0.01 | 4.24 ± 0.07 | −11.55 ± 0.08 | 3.43 ± 0.50 |
| Oroxyloside | −3.32 ± 0.08 | 3690.00 ± 551.54 | −6.16 ± 0.04 | 30.84 ± 1.90 | −9.41 ± 0.02 | 127.50 ± 4.95 |
| Fluoxetine (R) | −4.35 ± 0.05 | 652.97 ± 54.98 | −5.61 ± 0.06 | 77.65 ± 8.25 | −7.35 ± 0.07 | 4093.33 ± 475.01 |
| Fluoxetine (S) | −4.14 ± 0.05 | 928.59 ± 79.41 | −5.90 ± 0.03 | 47.15 ± 2.48 | −7.63 ± 0.03 | 2543.33 ± 123.42 |
| Albiflorin | −5.05 ± 0.30 | 211.37 ± 52.00 | −6.63 ± 0.16 | 14.23 ± 3.77 | −10.66 ± 0.50 | 23.85 ± 3.12 |
| Paeonflorin | −4.41 ± 0.04 | 591.13 ± 29.66 | −7.83 ± 0.21 | 2.09 ± 0.27 | −11.25 ± 0.03 | 5.45 ± 0.07 |
| Pentagalloyl-β-D-glucose | −0.67 ± 0.01 | 320580.00 ± 150.00 | −2.39 ± 0.49 | 19090.00 ± 3490.00 | −6.09 ± 0.21 | 35.50 ± 1.27 |
| MG-132 | −3.50 ± 0.63 | 47053.00 ± 1090.00 | −7.75 ± 0.35 | 2.31 ± 0.33 | −9.07 ± 0.29 | 172.10 ± 27.01 |
IκK, IκB kinase; IκK, NEMO. NF-κB essential modulator; NF-κB, nuclear factor kappa; light, chain-enhancer of activated B cells.
Figure 9Visualization of molecular docking of chemical compounds isolated from FAEW to IκK.
Figure 10Visualization of molecular docking of chemical compounds isolated from FAEW to p65-RelA.
Literature review on the pharmacological activity of the compounds from FAEW.
| Paeoniflorin | Anti-inflammation and oxidative stress (Dong et al., | Parkinson's disease (Gu et al., | Rheumatoid arthritis (Chen et al., |
| Albiflorin | Oxidative stress (Suh et al., | Anti-depression (Song et al., | Muscle cramps and abdominal pains (Sadakane et al., |
| Baicalin | Inflammation (Min et al., | Alcoholic liver injury (Wang et al., | Ulcerative colitis (Yu et al., |
| Isoliquiritin | Anti-allergic activity (Kaur et al., | Depression (Wang et al., | Depression (Su et al., |
| Liquiritin | Neuroprotection (Teng et al., | Cognitive deficits (Jia et al., | Melisma (Amer and Metwalli, |
| β-hydroxy-DHP | Apoptosis (Rafi et al., | ||
| Isoliquiritin apioside | Anti-genotoxic (Kaur et al., | ||
| Oroxyloside | Colitis (Wang et al., | ||
Literature review of the effect of chemical constituents of FAEW against NF-κB.
| Paeoniflorin | Parkinson's disease (Liu et al., | Renal function (Liu et al., |
| Baicalin | Myofibroblast differentiation (Shin et al., | Asthma (Liu et al., |
| Isoliquiritin | Inflammatory responses (Kim et al., | |
| Liquiritin | Endothelial dysfunction (Zhang et al., | Myocardial fibrosis (Zhang et al., |
| Oroxyloside | Colitis (Wang et al., | |
Hydrogen bonds and amino acid residues identified by molecular docking of chemical compounds of FAEW to proteins of the NF-κB pathway.
| IκK | Baicalin | Thr23, Val29, Ala42, Lys44, Met65, Met96, Glu97, Tyr98, Cys99, Asp103, Val152, Ile165, Asp166, Leu167 | |
| β-hydroxy-DHP | Lys44 | Thr23, Val29, Ala42, Lys44, Met96, Glu97, Ile165, Asp166, Leu167 | |
| Isoliquiritin | Cys99, Lys147 | Leu21, Thr23, Gly24, Val29, Ala42, Glu97, Tyr98, Cys99, Lys147, Glu149, Ile165, Asp166, Gly184 | |
| Isoliquiritin apioside | Lys44, Cys99 | Thr23, Gly24, Val29, Ala42, Lys44, Met96, Glu97, Tyr98, Cys99, Lys147, Glu149, Ile165, Asp166, Leu167, Gly184 | |
| Liquiritin | Lys147 | Leu21, Thr23, Gly24, Ala42, Glu97, Cys99, Lys147, Glu149, Val152, Ile165, Asp166 | |
| Ononin | Cys99, Lys147 | Leu21, Gly22, Thr23, Val29, Ala42, Val74, Met96, Glu97, Tyr98, Cys99, Lys147, Val152, Ile165, Thr185 | |
| Oroxyloside | Cys99 | Thr23, Val29, Ala42, Lys44, Met65, Met96, Glu97, Tyr98, Cys99, Asp103, Glu149, Val152, Ile165, Asp166, Leu167 | |
| Fluoxetine (R) | Gly24, Val29, Ala42, Lys44, Met65, Met96, Tyr98, Ile165, Asp166, Leu167 | ||
| Fluoxetine (S) | Gly24, Val29, Lys44, Met96, Tyr98, Cys99, Ile165, Asp166, Leu167 | ||
| Albiflorin | Cys99 | Gly22, Val29, Lys44, Met 65, Val74, Met96, Glu97, Tyr98, Cys99, Asp103, Glu149, Asn150, Ile165, Asp166, Leu167 | |
| Paeoniflorin | Gly22, Val29, Lys44, Met65, Val74, Met96, Glu97, Tyr98, Cys99, Asp103, Glu149, Asn150, Ile165, Asp166, Leu167 | ||
| Pentagalloyl-β-D-glucose | Glu100 | Leu21, Gly22, Thr23, Val29, Ala42, Lys44, Glu61, Met65, Val73, Val74, Ala76, Leu94, Met96, Tyr98, Cys99, Glu100, Gly102, Asp103, Glu149, Asn150, Ile151, Val152, Ile165, Asp166, Leu167 | |
| MG-132 | Leu21, Thr23, Val29, Ala42, Met65, Val73, Val74, Met96, Glu97, Tyr98, Asp103, Val152, Ile164, Ile165, Asp166, Leu167 | ||
| p65-RelA | Baicalin | DA18, Lys122 | DT8, DT9, DT10, DA18, DG19, DT20, DC21, Lys122, Arg124 |
| β-hydroxy-DHP | DG19 | DT8, DT9,DT10, DA18, DG19, DT20, DC21 | |
| Isoliquiritin | DA18, DG19 | DC7, DT8, DT9, DT10, DA18, DG19, DT20, DC21, Lys123 | |
| Isoliquiritin apioside | DA18 | DT8, DT10, DA18, DG19, DC21 | |
| Liquiritin | DG19 | DT8, DT9, DA18, DG19, DT20, DC21, Lys123 | |
| Ononin | DG19 | DC7, DT8, DT9, DT10, DA18, DG19, DT20, DC21, Lys445 | |
| Oroxyloside | DG19, Lys122, Arg124 | DT8, DT9, DT10, DG19, DT20, DC21, Lys122, Lys123, Arg124 | |
| Fluoxetine (R) | DA18, DG19 | DC7, DT8, DT9, DT10, DA18, DG19, DT20, DC21 | |
| Fluoxetine (S) | DG19 | DC7, DT8, DT9,DT10, DG19, DT20, DC21 | |
| Albiflorin | DG19 | DC7, DT8, DT9, DT10, DA18, DG19, DT20, DC21, Arg124 | |
| Paeoniflorin | DG19 | DC7,DT8, DT9, DT10, DA18, DG19, DC21, DC22, Arg124 | |
| Pentagalloyl-β-D-glucose | DG19 | DC7, DC8, DT9, DG19, DT20, DC21, DC22, Lys123, Arg124 | |
| MG-132 | DG19 | DA6, DC7, DT8, DT9, DT10, DA18, DG19, DT20, DC21, DC22, Lys123 |